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Novelty and impact of this paper 
Although there is an increasing amount of evidence relating to the relationship between type-2 
diabetes and cancer, very little is known about the relationship between the latter and type-1 
diabetes. This review is the first to gather together all the epidemiological evidence in this regard 
and explore whether or not there is consistent evidence of an association between the two diseases. 
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Abstract 
 
This review explores the epidemiological evidence relating to type-1 diabetes (T1DM) and cancer 
incidence and mortality. Mortality rates among those with T1DM are higher in every age group 
compared with the general population; the majority of this mortality is due to factors related to the 
consequences of diabetes, such as cardiovascular and renal diseases. For over 100 years, researchers 
have explored the relationships between diabetes and cancer and although there is now a large 
body of work on the subject, consensus has not been reached. Such research has tended to focus 
upon type-2 diabetes (T2DM), with the result that very little is known about T1DM and cancer. As 
incidence of T1DM increases, by around 3% annually among children, the need for further research 
into its impact upon cancer incidence and mortality increases. Within this review, findings varied by 
study method utilised, T1DM definition used, study region and outcome measure explored. None of 
the case-control studies found a statistically significant link between the two diseases, while both of 
the meta-analyses did. Cohort studies produced mixed results. There were also mixed findings 
among research that defined T1DM in the same way (for example defining individuals with the 
disease as those diagnosed with diabetes before 30 years of age). The review found a number of 
studies which explored cause-specific cancer mortality among those with diabetes; such studies also 
had mixed findings. This inconsistency within results suggests the need for further research in order 
to understand better the potential relationships between T1DM and cancer. 
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Introduction 
 
Type-1 diabetes mellitus is a chronic condition which typically develops in childhood and is caused by 
the destruction of the β-cells within the pancreas, which leaves the body deficient in insulin.(1) 
Because of this, individuals with the disease require the use of exogenous insulin for survival. This 
form of the disease accounts for around 5-15% of all cases of diabetes mellitus, equating to around 
290,000 individuals in the UK and over 33 million globally.(2,3) Research also indicates that, Europe-
wide and internationally, incidence of the disease in children is increasing by around 3% annually. 
Although the cause of this is unclear, contributing factors appear to relate to the interplay between 
genes and the environment, and to better diagnosis and monitoring of the disease within countries 
that previously did not undertake such work.(4,5) Type-1 diabetes is associated with an increase in 
mortality at every age, with some estimates placing it at five to ten times higher among those with 
the disease.(6) The excess mortality found within this group is related primarily to metabolic 
complications of diabetes which result in increased rates of cardiovascular and renal disease.(7) 
 
Investigations attempting to detail the link between diabetes mellitus, hyperglycaemia and cancer 
started in the late 1800s with the work of Freund(8) and Tuffier(9). Since then, a wealth of 
epidemiological research has been undertaken with resultant mixed findings. Even though a 
definitive answer has not been found, it does appear that diabetes influences the incidence of a 
number of cancers. Included in this group are cancers with a considerable increase in incidence 
(endometrium, pancreas, and liver), those with a moderate increase (breast and bladder), others for 
which the findings are inconclusive (kidney and non-Hodgkins lymphoma) and those with a lower 
incidence (prostate).(10) The majority of the research to date has focussed upon the link between 
type-2 diabetes and its impact upon cancer incidence, with some commentators questioning the 
validity of extrapolating such findings to type-1 diabetes.(11) Other studies have focussed upon 
diabetes in general and have not differentiated between type-1 and type-2 diabetes. Research has 
also begun to explore the effect that the use of different types of exogenous insulin, and other 
diabetic drugs, have upon the risk of developing cancer, again with mixed findings.(12–14) This 
review was undertaken to enable greater awareness of the potential relationship between type-1 
diabetes and cancer. The review concludes with a number of suggestions for the development of 
future epidemiological research in this area.   
Material and methods 
 
Study identification 
A literature search was undertaken within PubMed and Google Scholar to identify research with a 
focus on diabetes mellitus and its impact upon cancer incidence and mortality.  Searches utilised the 
terms “diabetes”, “type 1 diabetes” “insulin treated diabetes mellitus” “IDDM”, “early onset 
diabetes”, “juvenile onset”, “young onset”, or  “type-1 diabetes mellitus” “T1DM”,  and “cancer”, 
“neoplasm”, “malignancy”, “incidence” or “mortality”. The references cited within each article were 
then reviewed in order to elicit further relevant articles. 
Inclusion/exclusion of reports 
The review includes only those reports that document research specifically focussed upon exploring 
the link between type-1 diabetes and cancer. A large number of reports detail evidence relating to 
the excess all-cause mortality experienced by those with type-1 diabetes and the references for 
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these reports were also reviewed. Studies were excluded in instances when they did not analyse the 
two different types of diabetes separately, or when it was unclear which type of diabetes was under 
analysis. The only instances where studies of this nature have been included in the review is when 
the focus of the study was upon insulin use and the age group of the cohort was young enough to be 
composed mainly of those with type 1 diabetes. If two studies utilised the same cohort, the earlier 
study was excluded from the review. Studies were also excluded if they detailed the excess mortality 
of a type-1 diabetic cohort but did not specifically analyse cancer incidence or mortality compared 
with the general population, or other specified control group.  Studies were excluded if they did not 
give information about the precision of their measurement, such as 95% Confidence intervals (CI) or 
p-values. Figure 1 details the literature selection. 
 
Figure 1: Selection of articles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
As can be seen from table 1, there were mixed findings, depending on the study method used. 
Mixed results were found among cohort studies. None of the case-control studies found a 
statistically significant link between the two diseases, while both of the meta-analyses (which 
included both study designs) did. There were also mixed findings among research that defined type-
1 diabetes in the same way. For example, three studies used diagnosis before the age of 30 as being 
indicative of the disease: two found no statistically significant relationship while one did. The rest of 
this section explores the results of the research found within this review, based upon the method 
used within the study. 
 
Cohort Studies 
A UK study found increased mortality among women with type-1 diabetes for ovarian cancer (SMR 
2.90, 95% CI 1.45-5.19); the same was not found to be true for any other cancer site or all cancers 
combined, the latter gave an SMR 0.90 (95% CI 0.75-1.08).(15) A key limitation of this study was that 
a large proportion of their subjects (20,676 out of a total of 28,900) were under the age of 50 at 
follow up. This is known to be a period when cancer incidence is lower than in later life; 63% of 
Page 4 of 16
John Wiley & Sons, Inc.
International Journal of Cancer
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 5 
cancers are diagnosed in those over the age of 65 and only 5.4% of cancer in men, and 8.9% of those 
in women, occur under the age of 45.(16,17) 
 
A Swedish study found a standardized mortality ratio (SMR) of 1.73 (95% CI 1.45-2.05) among its 
type-1 diabetic cohort compared with the general population.(18) In support of this, a New Zealand 
study found an SMR for cancer of 12.96 (95% CI 3.36-22.57) among those diagnosed with type-1 
diabetes compared with the general population.(19) The CI is wide and this may be due to there 
being only seven observed cases of cancer among those diagnosed with diabetes under the age of 
30 (the measure used within the study as indicative of type-1 diabetes).  The US Allegheny County 
Type-1 Diabetes Registry cohort study investigated cause-specific mortality among its cohort of 
those with type-1 diabetes (n=1,043). They found no statistically significant association between the 
two diseases (SMR= 1.2, 95% CI 0.5-2.0) compared with the general population.(20) The lack of 
statistical significance in this study is likely to be heavily influenced by the small number of cancer 
deaths and the consequent effect on statistical power. 
Only a few reports have focussed upon cause-specific mortality among those with type-1 diabetes; 
among these a smaller number still investigated cancer mortality. The reason for this is likely to be 
the excess of mortality among those with type-1 diabetes caused by complications of the disease 
itself, such as renal disease and cardiovascular disease.(21) A UK study linked cause of death data to 
a register of those with diabetes and found that those with type-1 diabetes only accounted for 18 
(5%) of all deaths within the study; because of this they did not undertake separate analysis for 
cause of death among those with this form of diabetes.(22) Other studies were characterised by 
their inclusion of numbers of concurrent type-1 diabetes and cancer too small to elicit statistically 
viable results.(23–26)  
A Danish study found no overall increase in cancer cases among those with type 1 diabetes 
compared with the general population.(27) More detailed analysis showed that, for site specific 
cancers, only that of the pancreas had a statistically significant increase (RR=2.53, 95% CI = 1.17-
5.47). However, further analysis showed that, once cases were excluded where diabetes was an 
early indication of the presence of cancer, the relationship was no longer statistically significant (RR= 
1.69, p=0.29). In terms of age and gender, only men between the ages of 0-54 had an increased risk 
of cancer (RR=2.04, 95% CI= 1.11-3.74); although this result may reflect the small numbers within 
the studies other groups rather than the real effect type-1 diabetes has upon cancer incidence.  
There were also only a small number of cohort studies which focus upon type-1 diabetes and cancer 
incidence. A Swedish study found a 17% increase in cancer among those with type-1 diabetes 
compared with the general population.(28) At the same time, if analysis excluded specific time 
periods after diagnosis (based on either one or five years) no significant increase in standardized 
incidence ratio (SIR) was found. Exclusion of the first year (SIR 1.07, 95% CI 0.94-1.22) was similar to 
analysis for exclusion of first five years (SIR 1.09, 95% CI 0.96-1.25). This finding may support the 
reverse causality hypothesis-that diabetes is the result of an undiagnosed cancer, rather than the 
other way round or it could be the consequence of small numbers within the study. In terms of site-
specific cancers the study found increased SIRs for those of the stomach (3.36, 95% CI 1.44-6.66), 
squamous cell carcinoma of the skin (4.96, 95% CI 2.83-8.07) and leukaemia (2.02 95% CI 1.15-3.29). 
These SIRs were those which excluded the first five years of follow up after diagnosis of type-1 
diabetes, with significance remaining stable across all the three follow-up intervals of all cases, one 
year follow-up exclusion, and five years exclusion. Gender was a key factor in excess cancer 
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incidence. After exclusion of the first year following type-1 diabetes diagnosis, SIR only remained 
increased among women.  This statistical significance was also only for cancers of the skin (SIR 9.40, 
95% CI 5.12-15.82) and leukaemia (2.55, 95% CI 1.26-4.57). The number of visits an individual made 
to hospital was also found to be a risk factor for cancer, but the researchers were unsure whether 
this was due to the increased chance of a cancer being diagnosed within more frequent visits to 
hospital or because there was an association between type-1 diabetes and cancer.  
A Danish cohort study found mixed results depending on cancer site.(29) Among those defined as 
having type-1 diabetes (hospitalised for diabetes within the study period before the age of 50) the 
SIR for all cancers was 1.1, 95% CI 1.0-1.2; only cancers of the mouth and pharynx (SIR 1.8, 95% CI 
1.2-2.6) and liver (SIR 4.8, 95% CI 2.8-7.7) were increased among this group. For cancers of the 
pancreas, lung and kidney non-statistically significant increases were found (SIR 1.4, 95% CI 0.7-2.3, 
SIR 1.3, 1.0-1.6 and 1.6, 1.0-2.4 respectively). A third Swedish cohort study found an overall SIR for 
cancer of 1.2 (95% CI 1.0-1.3) among those with type-1 diabetes compared with the general 
population.(30) For site-specific cancers significant increases in SIR were found for those of the 
stomach (2.3, 95% CI 1.1-4.1), cervix (1.6, CI 1.1-2.2), and endometrium (2.7, CI 1.4-4.7). 
Case-control studies 
A case-control study (7,713 cases, 38,518 controls) undertaken in the UK explored all-cause and 
cause-specific mortality among those with type-1 diabetes compared with the general 
population.(31) They found no difference in the hazard ratios for cancer mortality between the two 
groups (HR=1.05, 95% CI 0.72-1.52). An Italian case-control study exploring the link between 
endometrial cancer incidence and diabetes (type-1 diabetes and type-2 diabetes, assessed 
separately) found no link between type-1 diabetes and the disease (OR=1.0, 95% CI 0.3-3.4) but only 
four cases with type-1 diabetes were included in the study.(32) In support of this finding, a second 
study which included 14,000 individuals aged 30-89 with diabetes, found no statistically significant 
association (at the 5% level) between a range of site- specific cancers and the disease.(33) 
 
Meta-analyses and systematic reviews 
A meta-analysis of the link between diabetes and endometrial cancer found an association between 
the two diseases (RR=3.15, 95% CI 1.07-9.29).(34) This was based on three studies, one of which was 
a Swedish case-control study which had few women with type-1 diabetes (<10) and found a relative 
risk (RR) of 13.3, with a wide CI of 3.1-56.4.(35) The other two studies are those of Swerdlow (UK) et 
al and Zendehdel et al (Sweden), mentioned earlier in this review.(15,30) 
 
A systematic review and meta-analysis focussed upon type-1 diabetes and the incidence of 
pancreatic cancer.(36) Within the meta-analysis a relative risk of 2.00 (95% CI 1.37-3.01) was found 
for pancreatic cancer among those with type-1 diabetes. The meta-analysis was based on 39 
concurrent cases of the two diseases. The researchers themselves reported that the study was 
limited by the small number of studies published in this area; there were an even smaller number 
that were published with sufficient concurrent cases of type-1 diabetes and pancreatic cancer; Ekoe 
et al found only one case while La Vecchia found three.(37,38) Only two studies had more than five 
cases among those with type-1 diabetes; the first of these is the Wideroff study mentioned above 
and the second found an increased relative risk of pancreatic cancer among those with type-1 
diabetes (RR 2.23, 95% CI 1.08-4.58.(39) Three of the studies included in the analysis had no 
concurrent cases of type-1 diabetes and pancreatic cancer.(33,40,41)  
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Table 1: Key findings of research exploring the relationship between type-1 diabetes and cancer 
Study 
method  
Country Sample  Case definition (type-1 diabetes) Outcome 
measure 
Risk of cancer among T1DM 
participants (95% CI or p-
value)  
Risk of site-specific cancers  
(95% CI or p-value) 
Cohort(27) Denmark 1,499 insulin treated individuals  Insulin use Incidence Men RR=1.37 (1.03-1.83), 
Women RR=1.08 (0.77-1.51),  
Pancreas RR=2.53 (1.17-5.47); RR=1.69 
(p=0.29) once cases excluded where 
diabetes an indicator of cancer 
Cohort(18) Sweden 144,427 participants with diabetes  Hospitalisation for diabetes <age 40 Mortality RR=1.73 (1.45-2.05) N/A 
Cohort(28) Sweden 24,052 type-1 diabetic patients  Diagnosis <age 21 Incidence RR=1.17 (1.04-1.33),  Stomach RR=3.36 (1.44-6.66), skin RR=4.96 
(2.83-8.07), leukaemia RR=2.02 (1.15-3.29) 
Cohort(19) New 
Zealand 
966 insulin treated participants 
including 427 with type-1 diabetes 
Diagnosis <age 30 Mortality SMR=12.96 (3.36-22.57) N/A 
Cohort(20) USA 1,043 type-1 diabetic patients  Diagnosis <age 18 Mortality SMR=1.2 (0.5-2.0) N/A 
Cohort(15) UK 28,900 insulin treated diabetics 
including 23,834 with type-1 diabetes 
Diagnosis <age 30 Mortality SMR=0.90 (0.75-1.08),  Ovarian SMR=2.90, (1.45-5.19) 
Cohort (29) Denmark 109,581 individuals with diabetes Hospitalised with diabetes < age 50 Incidence SIR 1.1 (1.0-1.2) Liver SIR= 4.8 (2.8-7.7), mouth and pharynx 
SIR=1.8 (1.2-2.6) 
Cohort(30) Sweden 29,187 diabetes patients Hospitalisation for diabetes <age 30 Incidence SIR=1.2 (1.0-1.3) N/A 
Case-
control(31) 
UK 7,713 cases of type-1 diabetes and 
38,518 controls  
Those currently on insulin and aged <35 
at treatment or <35 years at diagnosis of 
diabetes 
Mortality HR=1.05 (0.72-1.52) N/A 
Case-
control(32) 
Italy 752 diabetic women with endometrial 
cancer and 2,606 admitted to the 
same hospitals  
Diagnosis <age 40 Incidence OR=1.0 (0.3-3.4) N/A 
Case-
control(33) 
USA 14,000 participants with diabetes 
aged 30-89 
Diagnosed with diabetes < age 29 Incidence Not statistically significant (at 
the p<0.05 level) 
N/A 
Meta-analysis(34) I case-control and 2 cohort studies (15,30,35) Incidence N/A Endometrial RR=3.15 (1.07-9.92) 
Meta-analysis(36) 3 cohort and 6 case-control studies Incidence N/A Pancreatic RR=2.00 (1.37-3.01) 
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Discussion 
 
This review of the epidemiological literature, relating to type-1 diabetes and cancer incidence and 
mortality, illustrates that there is still much we need to clarify about the relationship between the two 
diseases. The findings of the cohort studies were heterogeneous, for example the New Zealand study 
found an increased SMR of 12.96 (95% CI 3.36-22.57) while a UK study did not find an increase in cancer 
mortality among those with type-1 diabetes (SMR 0.09, 95% CI 0.75-1.08).(19,31) Neither of the case-
control studies found an association between type-1 diabetes and cancer but the meta-analyses did for 
both pancreatic and endometrial cancer (RR 2.0, CI 1.37-3.01 and RR 3.15, CI 1.07-9.92 
respectively).(34,36)  When studies were grouped into those that focussed upon either cancer mortality 
or incidence there was still no uniformity within the results. 
 
Although a small number of reports have been specifically focussed upon the two diseases, many of 
these used different criteria to identify type-1 diabetes (related to age at first diagnosis or age at first 
hospitalisation for diabetes). The inclusion criteria for a case of type-1 diabetes within different studies 
ranged from disease diagnosis from ages <18 to those <40 years old. This makes comparison across 
studies difficult, although the use of similar criteria did not generate homogeneity within results. It is 
likely that the younger classification of type-1 diabetes is more likely to capture a cohort which most 
closely matches the true type-1 diabetic population. One study found that using diagnosis before the age 
of 21 years as the cut-off criterion was specific enough to create a cohort which contained only 2% with 
type-2 diabetes.(28) Future research should carefully consider the specificity of the criteria they use in 
this regard. 
At the same time, studies which include younger cohorts are likely to contain fewer cases of cancer 
within a given follow-up period, thus reducing their statistical power considerably. One of the key issues 
with undertaking population based studies of the links between type-1 diabetes and cancer is that the 
former is relatively rare and, depending on the site of the cancer, the latter may also be relatively 
infrequent. The result has been that, when population-based studies have focussed specifically on 
cancer incidence and/or mortality, as well as differentiating between type-1 and type-2 diabetes, they 
produced small numbers of incident cancers among participants with type-1 diabetes.(42–44) Research 
could be improved through the use of larger cohorts and/or longer follow-up periods in order to 
generate enough concurrent cases of type-1 diabetes and cancer. 
The study from Denmark, which found an increase in risk of cancer among men aged 0-54 years, is of 
particular interest.(27) This age group was most likely to represent those with type-1 diabetes in the 
study period (1970-1980s), and may represent the true rate of cancer among those with the disease. 
Although this study found no increase in cancer risk among women, further exploration is needed to 
clarify this result.  The use of an exclusion period within some of the studies is also interesting to note in 
relation to the issue of reverse causality. Future research could explore the usefulness of this method in 
terms of exploring the causal pathway between diabetes and cancer (or whether or not it is vice-versa).  
The heterogeneity of findings supports the need for further investigation. The paucity of research in this 
area further illustrates the need for the development of research focused upon the two diseases. Studies 
undertaken in the future could utilise large-scale datasets with sufficient numbers of cases with type-1 
diabetes and controls, for example primary care records used for research such as the GPRD (General 
Practice Research Database) or THIN (The Health Improvement Network) in the UK. Such research would 
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enable a clearer understanding of a number of key epidemiological areas with respect to the relationship 
between type-1 diabetes and cancer. Future research could be undertaken to better understand the 
relationship between type-1 diabetes and: 
• overall cancer risk, 
• risk of site-specific cancers, 
• cancer mortality, 
• mortality after treatment for cancer, and 
• the impact that the use of exogenous insulin, and other diabetic medications, have upon cancer 
incidence. 
If an association is found between the two diseases, then further research may be required which 
explores, in greater detail than previous studies, the differences in type-1 diabetes and cancer relating to 
gender, race and other demographic and socioeconomic  factors; as well as the potential regional 
variations in diagnosis and treatment of both conditions. Although individuals with type-1 diabetes all 
require exogenous insulin for survival there may be differences in cancer risk dependent upon the type 
of insulin administered. At the same time, there is some evidence that individuals with diabetes who 
then go on to develop cancer are diagnosed at a later stage of the disease and may receive differing 
treatment regimens compared with those without diabetes.(45,46) The way that cancer is treated also 
differs by region and country, which will further impact upon cancer survival. All of these issues require 
further exploration. Research has begun to explore the biological basis for the increased all-cause and 
cause-specific mortality found among those with type-1 diabetes; key findings suggest that circulating 
adiponectin, the sharing of aetiological causes, complications caused by type-1 diabetes, and raised BMI 
may each contribute to increased mortality among those with type-1 diabetes compared with the 
general population.(10,47) Further research should also be undertaken which enables a better 
understanding of the biological causes of this differing mortality and enables interventions to be 
developed which address it. 
Conclusion 
 
Type-1 diabetes is a chronic condition relating to poor glycaemic control which appears to be increasing 
in incidence. Given the large number of individuals with the disease globally, even small increases in the 
relative risk of cancer incidence and/or mortality among this group will increase the total burden of 
cancer considerably. Those with the disease have increased mortality at every age following diagnosis, 
mainly due to complications of the disease itself and cardiovascular and renal disease.  An understanding 
of the potential association between type-1 diabetes and cancer will become increasingly important as 
improvements are made in the control and prevention of cardiovascular disease, enabling those with 
diabetes to live longer lives (which in turn increases the risk of developing cancer). Better understanding 
of the relationship between the two diseases also enables the development of interventions to reduce 
potential excess mortality. 
 
Current epidemiological research investigating the link between type-1 diabetes and cancer has resulted 
in mixed findings, which varied by the research methods used. Case-control studies have consistently not 
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found a statistically significant link between the two diseases, while meta-analyses have. Cohort studies 
have resulted in mixed findings and there appears to be heterogeneous results within studies that utilise 
the same criteria for a diagnosis of type-1 diabetes (such as being diagnosed with diabetes before the 
age of 30). Although there is heterogeneity within the results, it does appear that those with type-1 
diabetes either have the same or an increased risk of cancer incidence and/or mortality from the 
disease. The inconsistency within study findings strongly suggests the need for further detailed research 
to be undertaken which explores the nature of the relationship between type-1 diabetes and cancer. 
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Figure 1: Selection of articles 
 
Number of citations identified n=1736 
Excluded after reviewing titles and abstracts n=1693 
Articles included in detailed review n=43 
Excluded after reviewing full articles n=21 
• 10 articles did not differentiate between 
type-1 and type-2 diabetes 
• 5 articles no mention of cancer 
• 2 articles used the same dataset (so 1 
excluded) 
• 5 articles discussed insulin use, but did not 
differentiate between  type-1 and type-2 
diabetes  
 
Articles included in review: n=22 
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Table 1: Key findings of research exploring the relationship between type-1 diabetes and cancer 
 
Study 
method  
Country Sample  Case definition (type-1 diabetes) Outcome 
measure 
Risk of cancer among T1DM 
participants (95% CI or p-value)  
Risk of site-specific cancers  
(95% CI or p-value) 
Cohort(27) Denmark 1,499 insulin treated individuals  Insulin use Incidence Men RR=1.37 (1.03-1.83), Women 
RR=1.08 (0.77-1.51),  
Pancreas RR=2.53 (1.17-5.47); RR=1.69 (p=0.29) 
once cases excluded where diabetes an indicator of 
cancer 
Cohort(18) Sweden 144,427 participants with diabetes  Hospitalisation for diabetes <age 40 Mortality RR=1.73 (1.45-2.05) N/A 
Cohort(28) Sweden 24,052 type-1 diabetic patients  Diagnosis <age 21 Incidence RR=1.17 (1.04-1.33),  Stomach RR=3.36 (1.44-6.66), skin RR=4.96 (2.83-
8.07), leukaemia RR=2.02 (1.15-3.29) 
Cohort(19) New 
Zealand 
966 insulin treated participants including 
427 with type-1 diabetes 
Diagnosis <age 30 Mortality SMR=12.96 (3.36-22.57) N/A 
Cohort(20) USA 1,043 type-1 diabetic patients  Diagnosis <age 18 Mortality SMR=1.2 (0.5-2.0) N/A 
Cohort(15) UK 28,900 insulin treated diabetics including 
23,834 with type-1 diabetes 
Diagnosis <age 30 Mortality SMR=0.90 (0.75-1.08),  Ovarian SMR=2.90, (1.45-5.19) 
Cohort (29) Denmark 109,581 individuals with diabetes Hospitalised with diabetes < age 50 Incidence SIR 1.1 (1.0-1.2) Liver SIR= 4.8 (2.8-7.7), mouth and pharynx SIR=1.8 
(1.2-2.6) 
Cohort(30) Sweden 29,187 diabetes patients Hospitalisation for diabetes <age 30 Incidence SIR=1.2 (1.0-1.3) N/A 
Case-
control(31) 
UK 7,713 cases of type-1 diabetes and 38,518 
controls  
Those currently on insulin and aged <35 at 
treatment or <35 years at diagnosis of 
diabetes 
Mortality HR=1.05 (0.72-1.52) N/A 
Case-
control(32) 
Italy 752 diabetic women with endometrial 
cancer and 2,606 admitted to the same 
hospitals  
Diagnosis <age 40 Incidence OR=1.0 (0.3-3.4) N/A 
Case-
control(33) 
USA 14,000 participants with diabetes aged 30-
89 
Diagnosed with diabetes < age 29 Incidence Not statistically significant (at the 
p<0.05 level) 
N/A 
Meta-analysis(34) I case-control and 2 cohort studies (15,30,35) Incidence N/A Endometrial RR=3.15 (1.07-9.92) 
Meta-analysis(36) 3 cohort and 6 case-control studies Incidence N/A Pancreatic RR=2.00 (1.37-3.01) 
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